Brad Crutchfield - 10X GENOMICS Chief Commercial Officer

All Insiders . Germany . 
Stock . 10X GENOMICS DL . Stakeholders . Insider . Brad Crutchfield
1KJ Stock  EUR 12.61  0.07  0.56%   

Insider

Brad Crutchfield is Chief Commercial Officer of 10X GENOMICS DL
Phone925 401 7300
Webhttp://www.10xgenomics.com

10X GENOMICS Management Efficiency

The company has return on total asset (ROA) of (0.0892) % which means that it has lost $0.0892 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2122) %, meaning that it generated substantial loss on money invested by shareholders. 10X GENOMICS's management efficiency ratios could be used to measure how well 10X GENOMICS manages its routine affairs as well as how well it operates its assets and liabilities.
10X GENOMICS DL has accumulated 70.82 M in total debt with debt to equity ratio (D/E) of 0.09, which may suggest the company is not taking enough advantage from borrowing. 10X GENOMICS DL has a current ratio of 6.56, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist 10X GENOMICS until it has trouble settling it off, either with new capital or with free cash flow. So, 10X GENOMICS's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like 10X GENOMICS DL sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for 10X to invest in growth at high rates of return. When we think about 10X GENOMICS's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Jonathan JDEvolent Health
55
Seth FrankEvolent Health
N/A
Weihao FangPing An Healthcare
50
Jun WuPing An Healthcare
57
Andrew TuritzTeladoc
50
Courtney McLeodTeladoc
N/A
Cheng LiuPing An Healthcare
48
Eckart PechCompugroup Medical SE
54
Luoqi ZangPing An Healthcare
42
Brent BowmanVeeva Systems
56
Emanuele MugnaniCompugroup Medical SE
53
Oliver BruzekCompugroup Medical SE
N/A
Jessica SomersEvolent Health
N/A
Michael FranzCompugroup Medical SE
N/A
Aammaad ShamsEvolent Health
39
Richard NapolitanoTeladoc
56
Michelle BucariaTeladoc
48
Claus JensenTeladoc
N/A
Karen DanielTeladoc
61
Hemant TanejaTeladoc
44
MAAA FSAEvolent Health
50
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California. 10X GENOMICS operates under Health Information Services classification in Germany and is traded on Frankfurt Stock Exchange. It employs 852 people. 10X GENOMICS DL (1KJ) is traded on Frankfurt Exchange in Germany and employs 1,243 people.

Management Performance

Return On Equity-0.21
Return On Asset-0.0892

10X GENOMICS DL Leadership Team

Elected by the shareholders, the 10X GENOMICS's board of directors comprises two types of representatives: 10X GENOMICS inside directors who are chosen from within the company, and outside directors, selected externally and held independent of 10X. The board's role is to monitor 10X GENOMICS's management team and ensure that shareholders' interests are well served. 10X GENOMICS's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, 10X GENOMICS's outside directors are responsible for providing unbiased perspectives on the board's policies.
Mathai Mammen, Independent Director
Bradford Crutchfield, Chief Commercial Officer
Jean Philibert, Chief People Officer
Benjamin Hindson, President Co-Founder, Chief Scientific Officer, Director
Brad Crutchfield, Chief Commercial Officer
Justin McAnear, Chief Financial Officer
Shehnaaz Suliman, Independent Director
Eric Whitaker, General Counsel
Serge Saxonov, Chief Executive Officer, Co-Founder, Director
Sridhar Kosaraju, Independent Director
Bryan Roberts, Independent Director
John Stuelpnagel, Independent Chairman of the Board
Kimberly Popovits, Independent Director

10X Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is 10X GENOMICS a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.21
Return On Asset-0.0892
Profit Margin(0.33) %
Operating Margin(0.28) %
Shares Outstanding95.6 M
Shares Owned By Insiders2.60 %
Shares Owned By Institutions99.56 %
Revenue503.71 M
Gross Profit416.4 M
EBITDA(117.15 M)

Currently Active Assets on Macroaxis

CCitigroup
GMGeneral Motors
FFord Motor
GMGeneral Motors
VVisa Class A

Other Information on Investing in 10X Stock

10X GENOMICS financial ratios help investors to determine whether 10X Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in 10X with respect to the benefits of owning 10X GENOMICS security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY